Registration Now Open for NPE2024: The Plastics Show
12.9.2023 19:34:00 EEST | Business Wire | Press release
The Plastics Industry Association (PLASTICS) announced today that NPE2024: The Plastics Show registrations are now open through May 2024. NPE2024 will be the most impactful trade show of the year for all plastics industry sectors in the U.S. and globally, with more than 55,000 attendees expected.
Every three years, NPE offers the plastics industry a global platform to highlight innovation across a show floor with more than 1.1 million net square feet of exhibit space at the Orange County Convention Center in Orlando, Fla. Matt Seaholm, President and CEO of PLASTICS, highlighted that NPE2024 will return bigger and better than ever, “We look forward to welcoming our industry back to NPE2024: The Plastics Show next May. The plastic industry serves a critical and sustainable role in modern life; this show will be a testament to that.”
“With sustainability at the center of everything produced at the show, attendees will witness new technologies and significant education opportunities to push us toward a more circular economy and help our industry continue to grow,” said Seaholm.
NPE2024 returns, with the theme Made for You, where attendees are front and center of all experiences happening at the show. The event, held May 6-10, 2024, will offer opportunities for everyone in the industry, even those just starting their career. Some notable experiences at NPE2024 include:
- Six technology zones with 2,000+ exhibitors showcasing their latest products and services
- More than 100 speaker presentations on trending topics that foster innovation, drive circularity and exemplify collaboration
- The brand-new NPE Circularity Hub where attendees will experience the plastics circular economy, from raw materials to go-to market consumer products
- Influential women in the plastics industry will share their success stories with those attending the Women in Plastics Breakfast
- More than 355 first-time exhibitors bringing to NPE2024 new products and perspectives
- The inaugural NPE Opening Night Party featuring the band Pop Rocks, games, food and drinks
NPE2024 attendees will gain exclusive access to the entire plastics supply chain, including machinery and equipment, raw materials, recycling and sustainability, automation and robotics, 3D and 4D printing, inspection, design, and more. NPE exhibitors service vital markets such as automotive, consumer products, recycling, packaging, medical, and building and construction.
Important dates to remember if planning on attending NPE2024:
- Attendee registration for NPE2024 opens on Tuesday, September 12, 2023
- Registration for the hotel room block also begins on Tuesday, September 12, 2023
- NPE2024 event dates are May 6-10, 2024, at the Orange County Convention Center in Orlando, Fla.
Tickets for NPE2024 range from $100 - $600; prices vary depending on early bird, advanced and on-site sales. Add-ons to the NPE Opening Night Party, Women in Plastics Breakfast, Seminarios Latinoamericanos, and 3D Printing for Plastic Processors are also available on a first-come, first-served basis, inquire for details.
“NPE2024 is at the forefront of the plastics future. If you want to further your career, grow your company or keep up with new trends and solutions, NPE2024 is where you need to be in May 2024. We encourage you to register today and start planning and customizing your experience as we continue to reveal all the exciting things happening at the event,” concluded Steve London, NPE2024 Committee Chair.
For more information about NPE2024: The Plastics Show and to register, visit: NPE.org.
The Plastics Industry Association (PLASTICS) is the only organization that supports the entire plastics supply chain, including Equipment Suppliers, Material Suppliers, Processors, and Recyclers, representing over one million workers in our $548 billion U.S. industry. PLASTICS advances the priorities of our members who are dedicated to investing in technologies that improve capabilities and advances in recycling and sustainability and providing essential products that allow for the protection and safety of our lives. Since 1937, PLASTICS has been working to make its members, and the seventh largest U.S. manufacturing industry, more globally competitive while supporting circularity through educational initiatives, industry-leading insights and events, convening opportunities and policy advocacy, including the largest plastics trade show in the Americas, NPE2024: The Plastics Show.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911029303/en/
Contact information
Elizabeth Domenech pr@npe.org
Camille Gallo cgallo@plasticsindustry.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom